[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60108857D1 - Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren - Google Patents

Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren

Info

Publication number
DE60108857D1
DE60108857D1 DE60108857T DE60108857T DE60108857D1 DE 60108857 D1 DE60108857 D1 DE 60108857D1 DE 60108857 T DE60108857 T DE 60108857T DE 60108857 T DE60108857 T DE 60108857T DE 60108857 D1 DE60108857 D1 DE 60108857D1
Authority
DE
Germany
Prior art keywords
methods
compositions
adreneer
receptors
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60108857T
Other languages
English (en)
Other versions
DE60108857T2 (de
Inventor
Ken Chow
W Gil
Ken Fang
E Garst
A Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60108857D1 publication Critical patent/DE60108857D1/de
Publication of DE60108857T2 publication Critical patent/DE60108857T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE60108857T 2000-04-13 2001-04-11 Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren Expired - Lifetime DE60108857T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US548410 2000-04-13
US09/548,410 US6313172B1 (en) 2000-04-13 2000-04-13 Methods and compositions for modulating alpha adrenergic receptor activity
PCT/US2001/011843 WO2001078703A2 (en) 2000-04-13 2001-04-11 Methods and compositions for modulating alpha adrenergic receptor activity

Publications (2)

Publication Number Publication Date
DE60108857D1 true DE60108857D1 (de) 2005-03-17
DE60108857T2 DE60108857T2 (de) 2005-12-29

Family

ID=24188743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60108857T Expired - Lifetime DE60108857T2 (de) 2000-04-13 2001-04-11 Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren

Country Status (12)

Country Link
US (1) US6313172B1 (de)
EP (1) EP1280525B1 (de)
JP (1) JP2003530430A (de)
AT (1) ATE288747T1 (de)
AU (2) AU2001253384B2 (de)
CA (1) CA2406057C (de)
DE (1) DE60108857T2 (de)
ES (1) ES2233627T3 (de)
HK (1) HK1051324A1 (de)
NZ (1) NZ522027A (de)
TW (1) TWI299662B (de)
WO (1) WO2001078703A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US6534542B2 (en) * 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
EP2002827A2 (de) 2001-12-05 2008-12-17 The Baylor College Of Medicine Verfahren und Zusammensetzungen zur Regulierung der Knochenbildung mittels Modulation des sympathischen Tonus
RU2339369C2 (ru) * 2002-02-13 2008-11-27 Витро-Ретинол Текнолоджиз, Инк. Лечение офтальмологических нарушений с использованием мочевины и ее производных
US7358269B2 (en) * 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
KR20050050124A (ko) * 2002-10-08 2005-05-27 알러간, 인코포레이티드 신경퇴화의 치료를 위한 알파 2ｂ 또는 2ｂ/2ｃ아드레날린성 수용체 아고니스트
EP1549314B1 (de) * 2002-10-08 2007-12-12 Allergan, Inc. Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20060293359A1 (en) * 2003-06-25 2006-12-28 Allergan, Inc. Methods and compositions for the treatment of diabetes
CA2566699C (en) 2004-05-11 2016-02-16 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
CA2581828A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
BRPI0613077A2 (pt) * 2005-06-29 2010-12-21 Allergan Inc agonistas alfa-2 andrenérgicos para o tratamento de dor
US7390829B2 (en) * 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
KR102013086B1 (ko) * 2010-08-16 2019-08-21 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562391A (en) * 1969-06-17 1971-02-09 American Cyanamid Co Method of suppressing inflammation in mammals
SU795462A3 (ru) * 1975-03-14 1981-01-07 Эдьт Дьедьесерведьесети Дьяр (Фирма) Способ получени тиокарбамидныхпРОизВОдНыХ
US4460602A (en) * 1981-06-30 1984-07-17 The Procter & Gamble Company Urea derivatives
GB8715357D0 (en) * 1987-06-30 1987-08-05 Sandoz Inst For Medical Resear Organic compounds
US4988688A (en) * 1989-08-02 1991-01-29 Warner-Lambert Company 4-(N-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents
HU210683B (en) * 1990-06-18 1995-06-28 Sandoz Ag Process for producing n-benzyl-n1-(phenyl-alkyl)-thiourea derivatives and pharmaceutical compositions containing the same
US5212176A (en) 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Also Published As

Publication number Publication date
DE60108857T2 (de) 2005-12-29
AU2001253384B2 (en) 2006-02-02
US6313172B1 (en) 2001-11-06
JP2003530430A (ja) 2003-10-14
WO2001078703A3 (en) 2002-03-21
NZ522027A (en) 2004-11-26
AU5338401A (en) 2001-10-30
HK1051324A1 (en) 2003-08-01
ES2233627T3 (es) 2005-06-16
EP1280525B1 (de) 2005-02-09
TWI299662B (en) 2008-08-11
CA2406057A1 (en) 2001-10-25
EP1280525A2 (de) 2003-02-05
ATE288747T1 (de) 2005-02-15
WO2001078703A2 (en) 2001-10-25
CA2406057C (en) 2009-08-04

Similar Documents

Publication Publication Date Title
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE483976T1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
ATE342097T1 (de) Elektroaktive pore
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
TR200200278T2 (tr) Kalsilitik bileşimler
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
ATE497604T1 (de) Selektive modulation von tumornekrosefaktor- rezeptoren in der therapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition